A selective aryl hydrocarbon receptor modulator 3,3'-Diindolylmethane inhibits gastric cancer cell growth

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Yin, Xiao Fei ^a   Chen, Jie ^a   Mao, Wei ^a   Wang, Yu Hong ^a   Chen, Min Hu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

3,3' Diindolylmethane; Aryl hydrocarbon receptor; Cytochrome P4501A1; Gastric cancer

Indexed keywords

3,3' DIINDOLYLMETHANE; AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450 1A1; RESVERATROL; 3,3'-DIINDOLYLMETHANE; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; STILBENE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL NUCLEUS; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOPLASM; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; WESTERN BLOTTING; BIOSYNTHESIS; CELL CYCLE; CELL GROWTH; CELL SURVIVAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; GENETICS; METABOLISM; PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

ANTICARCINOGENIC AGENTS; APOPTOSIS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; CYTOCHROME P-450 CYP1A1; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; INDOLES; RECEPTORS, ARYL HYDROCARBON; STILBENES; STOMACH NEOPLASMS;

EID: 84861009528     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-46     Document Type: Article

References (33)

1. Global cancer statistics. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, CA Cancer J Clin 2011 61 69 90 10.3322/caac.20107 21296855
2. Management of gastric adenocarcinoma. Khosravi Shahi P, de la Díaz Muñoz Espada VM, García Alfonso P, Encina García S, Izarzugaza Perón Y, Arranz Cozar JL, Hernández Marín B, Pérez Manga G, Clin Transl Oncol 2007 9 438 442 10.1007/s12094-007-0082-8 17652057
3. Role of the Ah receptor and the dioxin-inducible [Ah] gene battery in toxicity, cancer and signal transduction. Nebert DW, Puga A, Vasiliou V, Ann NY Acad Sci 1993 685 624 640 10.1111/j.1749-6632.1993.tb35928.x 8395783 (Pubitemid 23238548)
4. Recent advances in molecular diagnosis and therapy of gastric cancer. Chen J, Rocken C, Malfertheiner P, Ebert MP, Dig Dis 2004 22 380 385 10.1159/000083602 15812163 (Pubitemid 41201479)
5. Expression and activity of aryl hydrocarbon receptors in development and cancer. Gasiewicz TA, Crit Rev Eukaryot Gene Expr 2008 18 279 321 10.1615/CritRevEukarGeneExpr.v18.i4.10 18652561 (Pubitemid 351991362)
6. Overexpression of cytochrome P450 1B1 in advanced non-small cell lung cancer: a potential therapeutic target. Su JM, Lin P, Wang CK, Chang H, Anticancer Res 2009 29 509 515 19331196
7. A role for the aryl hydrocarbon receptor in mammary gland tumorigenesis. Schlezinger JJ, Liu D, Farago M, Seldin DC, Belguise K, Sonenshein GE, Sherr DH, Biol Chem 2006 387 1175 1187 16972784 (Pubitemid 44402063)
8. The selective aryl hydrocarbon receptor modulator 6-methyl-1,3,8- trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice. Fritz WA, Lin TM, Safe S, Moore RW, Peterson RE, Biochem Pharmacol 2009 77 1151 1160 10.1016/j.bcp.2008.12.015 19166822
9. Potential therapeutic significance of increased expression of aryl hydrocarbon receptor in human gastric cancer. Peng TL, Chen J, Mao W, Liu X, Tao Y, Chen LZ, Chen MH, World J Gastroenterol 2009 15 1719 1729 10.3748/wjg.15.1719 19360915
10. The aryl hydrocarbon receptor, more than a xenobiotic-interacting protein. Barouki R, Coumoul X, Fernandez-Salguero PM, FEBS Lett 2007 581 3608 3615 10.1016/j.febslet.2007.03.046 17412325 (Pubitemid 47080995)
11. Dioxin and cancer: a critical review. Cole P, Trichopoulos D, Pastides H, Starr T, Mandel JS, Regul Toxicol Pharmacol 2003 38 378 388 10.1016/j.yrtph.2003.08.002 14623487 (Pubitemid 37414825)
12. Structure-activity relationships of dietary indoles: a proposed mechanism of action as modifiers of xenobiotic metabolism. Bradfield CA, Bjeldanes LF, J Toxicol Environ Health 1987 21 311 323 10.1080/15287398709531021 3495667 (Pubitemid 17090147)
13. Indole-3-carbinol and diindolylmethane as aryl hydrocarbon (Ah) receptor agonists and antagonists in T47D human breast cancer cells. Chen I, Safe S, Bjeldanes L, Biochem Pharmacol 1996 51 1069 1076 10.1016/0006-2952(96)00060-3 8866829 (Pubitemid 26104627)
14. Activation of caspase-8 contributes to 3,3'-Diindolylmethane-induced apoptosis in colon cancer cells. Kim EJ, Park SY, Shin HK, Kwon DY, Surh YJ, Park JH, J Nutr 2007 137 31 36 17182797 (Pubitemid 46052855)
15. Increased aryl hydrocarbon receptor expression offers a potential therapeutic target in pancreatic cancer. Koliopanos A, Kleeff J, Xiao Y, Safe S, Zimmermann A, Büchler MW, Friess H, Oncogene 2002 21 6059 6070 10.1038/sj.onc.1205633 12203118
16. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Ciolino HP, Daschner PJ, Yeh GC, Cancer Res 1998 58 5707 5712 9865727 (Pubitemid 29006410)
17. Resveratrol, a natural aryl hydrocarbon receptor antagonist, protects lung from DNA damage and apoptosis caused by benzo[a]pyrene. Revel A, Raanani H, Younglai E, Xu J, Rogers I, Han R, Savouret JF, Casper RF, J Appl Toxicol 2003 23 255 261 10.1002/jat.916 12884409 (Pubitemid 36950295)
18. Dioxin: a review of its environmental effects and its aryl hydrocarbon receptor biology. Mandal PK, J Comp Physiol B 2005 175 221 230 10.1007/s00360-005-0483-3 15900503 (Pubitemid 40764087)
19. Mechanism of action and development of selective aryl hydrocarbon receptor modulators for treatment of hormone-dependent cancers (Review). Safe S, McDougal A, Int J Oncol 2002 20 1123 1128 12011988
20. Comparative study of aryl hydrocarbon receptor ligand activities of six chemicals in vitro and in vivo. Sugihara K, Okayama T, Kitamura S, Yamashita K, Yasuda M, Miyairi S, Minobe Y, Ohta S, Arch Toxicol 2008 82 5 11 10.1007/s00204-007-0232-3 17899013
21. Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane. Chen I, McDougal A, Wang F, Safe S, Carcinogenesis 1998 19 1631 1639 10.1093/carcin/19.9.1631 9771935 (Pubitemid 28441867)
22. Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation. Jellinck PH, Forkert PG, Riddick DS, Okey AB, Michnovicz JJ, Bradlow HL, Biochem Pharmacol 1993 45 1129 1136 10.1016/0006-2952(93)90258-X 8384853 (Pubitemid 23079991)
23. The mechanism of AH receptor protein downregulation (degradation) and its impact on AH receptormediated gene regulation. Pollenz RS, Chem Biol Interact 2002 141 41 61 10.1016/S0009-2797(02)00065-0 12213384 (Pubitemid 35223204)
24. Involvement of a post-transcriptional mechanism in the inhibition of CYP1A1 expression by resveratrol in breast cancer cells. Lee JE, Safe S, Biochem Pharmacol 2001 62 1113 1124 10.1016/S0006-2952(01)00763-8 11597580 (Pubitemid 32971677)
25. 3,30-Diindolylmethane (DIM) induces a G1 cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21(WAF1/CIP1) expression. Hong C, Kim HA, Firestone GL, Bjeldanes LF, Carcinogenesis 2002 23 1297 1305 10.1093/carcin/23.8.1297 12151347
26. Induction of G1 and G2/M cell cycle arrests by the dietary compound 3,3'-diindolylmethane in HT-29 human colon cancer cells. Choi HJ, Lim do Y, Park JH, BMC Gastroenterol 2009 9 39 10.1186/1471-230X-9-39 19480695
27. 3,3'-Diindolylmethane induces a G(1) arrest in human prostate cancer cells irrespective of androgen receptor and p53 status. Vivar OI, Lin CL, Firestone GL, Bjeldanes LF, Biochem Pharmacol 2009 78 469 476 10.1016/j.bcp.2009.05.008 19433067
28. 3,3'-Diindolylmethane (DIM) induces a G(1) cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21(WAF1/CIP1) expression. Hong C, Kim HA, Firestone GL, Bjeldanes LF, Carcinogenesis 2002 23 1297 1305 10.1093/carcin/23.8.1297 12151347
29. Anticancer properties of indole compounds: mechanism of apoptosis induction and role in chemotherapy. Ahmad A, Sakr WA, Rahman KM, Curr Drug Targets 2010 11 652 666 10.2174/138945010791170923 20298156
30. Gene expression profiling revealed survivin as a target of 3,3'-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Rahman KW, Li Y, Wang Z, Sarkar SH, Sarkar FH, Cancer Res 2006 66 4952 4960 10.1158/0008-5472.CAN-05-3918 16651453
31. Down-regulation of uPA and uPAR by 3,3'-diindolylmethane contributes to the inhibition of cell growth and migration of breast cancer cells. Ahmad A, Kong D, Wang Z, Sarkar SH, Banerjee S, Sarkar FH, J Cell Biochem 2009 108 916 925 10.1002/jcb.22323 19693769
32. Inactivation of NF-kappaB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Rahman KM, Ali S, Aboukameel A, Sarkar SH, Wang Z, Philip PA, Sakr WA, Raz A, Mol Cancer Ther 2007 6 2757 2765 10.1158/1535-7163.MCT-07-0336 17913854 (Pubitemid 350064073)
33. Front Selective growth regulatory and pro-apoptotic effects of DIM is mediated by AKT and NF-kappaB pathways in prostate cancer cells. Li Y, Chinni SR, Sarkar FH, Biosci 2005 10 236 243 (Pubitemid 40543031)